Difurunsi Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Difurunsi General Information
Description
Developer of recombinant virus technology designed for vaccine research and antiviral drug evaluation. The company utilizes a modular design-construct-verify-learn approach to perform targeted editing of viral vectors for genetic engineering, providing pharmaceutical companies with protease inhibitor screening systems, hpv pseudoviruses, inactivated virus products, live attenuated vaccines, oncolytic virus platforms and recombinant viral vectors to validate drug candidates within cellular microenvironments.
Contact Information
Website
www.diff-biotech.comCorporate Office
- Room 601, 6th Floor, Building C
- Number 688 Bin'an Road, Changhe Street, Binjiang District
- Hangzhou, Zhejiang 310052
- China
Corporate Office
- Room 601, 6th Floor, Building C
- Number 688 Bin'an Road, Changhe Street, Binjiang District
- Hangzhou, Zhejiang 310052
- China
Difurunsi Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 08-Jul-2026 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 17-Jun-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 17-Dec-2022 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 01-Dec-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Apr-2021 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 29-Apr-2020 | Completed | Generating Revenue |
Difurunsi Patents
Difurunsi Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-1446789-A | Production of benzenesulphonamides | Inactive | 27-Nov-1973 | ||
| GB-1445257-A | Preparation | Inactive | 04-Oct-1973 | ||
| GB-1441352-A | Preparation of a benzamide | Inactive | 17-Sep-1973 | ||
| GB-1439295-A | Hydroxylamine derivative and its preparation and conversion to n- diethylaminoethyl- 2 - methoxy - 5-methylsulphonylbenzamide | Inactive | 10-Sep-1973 | ||
| GB-1455595-A | Preparation of 2,5-disubstituted benzamides | Inactive | 12-Apr-1973 | C07D207/09 |
Difurunsi Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hefei Industry Investment Group | Venture Capital | Minority | ||
| Hangzhou Hi-Tech Financial Investment Group | Venture Capital | Minority | ||
| Hangzhou Tianhe Hi-Tech | Accelerator/Incubator | Minority | ||
| Shulan Junjie Capital | Venture Capital | Minority |
Difurunsi FAQs
-
When was Difurunsi founded?
Difurunsi was founded in 2017.
-
Where is Difurunsi headquartered?
Difurunsi is headquartered in Hangzhou, China.
-
What industry is Difurunsi in?
Difurunsi’s primary industry is Biotechnology.
-
Is Difurunsi a private or public company?
Difurunsi is a Private company.
-
What is Difurunsi’s current revenue?
The current revenue for Difurunsi is .
-
Who are Difurunsi’s investors?
Hefei Industry Investment Group, Hangzhou Hi-Tech Financial Investment Group, Hangzhou Tianhe Hi-Tech, and Shulan Junjie Capital have invested in Difurunsi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process